PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Financial Statements and ExhibitsItem 9.01.
|99.1||Press release, dated September 20, 2017|
PHASERX, INC. ExhibitEX-99.1 2 v475490_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency PhaseRx’s second enzyme replacement therapy to receive orphan drug designation for a Urea Cycle Disorder SEATTLE,…To view the full exhibit click
About PhaseRx, Inc. (NASDAQ:PZRX)
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.